TABLE OF CONTENTS
1 INTRODUCTION 43
1.1 OBJECTIVES OF THE STUDY 43
1.2 MARKET DEFINITION 43
1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET 43
1.4 LIMITATIONS 45
1.5 MARKETS COVERED 45
2 MARKET SEGMENTATION 48
2.1 MARKETS COVERED 48
2.2 GEOGRAPHICAL SCOPE 49
2.3 YEARS CONSIDERED FOR THE STUDY 50
2.4 CURRENCY AND PRICING 50
2.5 DBMR TRIPOD DATA VALIDATION MODEL 51
2.6 MULTIVARIATE MODELLING 54
2.7 PRODUCT TYPE LIFELINE CURVE 54
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 55
2.9 DBMR MARKET POSITION GRID 56
2.10 MARKET END USER COVERAGE GRID 57
2.11 VENDOR SHARE ANALYSIS 58
2.12 SECONDARY SOURCES 59
2.13 ASSUMPTIONS 59
3 EXECUTIVE SUMMARY 60
4 PREMIUM INSIGHTS 63
4.1 PORTERS FIVE FORCES 64
4.2 PESTEL ANALYSIS 65
5 INDUSTRY INSIGHTS: 66
6 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, REGULATIONS 67
6.1 REGULATORY SCENARIO IN THE U.S 67
6.2 REGULATORY SCENARIO IN AUSTRALIA 67
6.3 REGULATORY SCENARIO IN JAPAN 68
6.4 REGULATORY SCENARIO IN CHINA 68
7 MARKET OVERVIEW 70
7.1 DRIVERS 72
7.1.1 GROWING PREVALENCE OF COLORECTAL CANCER 72
7.1.2 RISE IN THE NUMBER OF PATIENTS SUFFERING FROM DIVERTICULITIS AND ULCERATIVE COLITIS. 72
7.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 72
7.2 RESTRAINTS 73
7.2.1 STRINGENT REGULATORY POLICIES 73
7.2.2 HIGH COST FOR THE COLORECTAL CANCER TREATMENTS. 73
7.3 OPPORTUNITIES 74
7.3.1 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 74
7.3.2 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 75
7.3.3 STRATEGIC INITIATIVES BY MARKET PLAYERS 75
7.4 CHALLENGES 76
7.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 76
7.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 77
8 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE 78
8.1 OVERVIEW 79
8.2 INSTRUMENTS 82
8.2.1 PATHOLOGY-BASED INSTRUMENTS 83
8.2.1.1 PCR INSTRUMENTS 83
8.2.1.2 SLIDE STAINING SYSTEMS 83
8.2.1.3 TISSUE PROCESSING SYSTEMS 84
8.2.1.4 CELL PROCESSORS 84
8.2.1.5 OTHER PATHOLOGY-BASED INSTRUMENTS 84
8.2.2 IMAGING INSTRUMENTS 84
8.2.2.1 ULTRASOUND SYSTEMS 84
8.2.2.2 CT SYSTEMS 84
8.2.2.3 MRI SYSTEMS 85
8.2.2.4 OTHERS 85
8.2.3 BIOPSY INSTRUMENTS 85
8.2.4 OTHERS 85
8.3 CONSUMABLES & ACCESSORIES 85
8.3.1 KITS 86
8.3.1.1 PCR KITS 86
8.3.1.2 DNA POLYMERASE KITS 86
8.3.1.3 NUCLEIC ACID ISOLATION KITS 86
8.3.1.4 OTHERS 87
8.3.2 REAGENTS 87
8.3.2.1 ASSAYS 87
8.3.2.2 BUFFERS 87
8.3.2.3 PRIMERS 87
8.3.2.4 OTHERS 87
8.3.3 OTHER CONSUMABLES 87
9 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY TEST TYPE 88
9.1 OVERVIEW 89
9.2 STOOL EXAMINATION 92
9.3 BLOOD TEST 92
9.3.1 COMPLETE BLOOD COUNT (CBC) 93
9.3.2 TUMOR MARKER TEST 94
9.3.3 LIVER ENZYME BLOOD TEST 94
9.4 IMAGING TEST 94
9.4.1 COMPUTED TOMOGRAPHY (CT) SCAN 95
9.4.2 MRI 95
9.4.3 ULTRASOUND 95
9.4.4 POSITION EMISSION TOMOGRAPHY (PET) 96
9.4.5 OTHERS 96
9.5 TUMOR MARKERS 96
9.5.1 CARCINOEMBRYONIC ANTIGEN (CEA) 97
9.5.2 CA19-9 BIOMARKER TEST 97
9.5.3 CA 50 MARKER TEST 97
9.5.4 OTHERS 97
9.6 BIOPSY 97
9.7 OTHERS 98
10 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER STAGES 99
10.1 OVERVIEW 100
10.2 STAGE III 103
10.3 STAGE IV 103
10.4 STAGE II 104
10.5 STAGE I 105
10.6 STAGE 0 105
11 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY AGE GROUP 107
11.1 OVERVIEW 108
11.2 GERIATRIC 111
11.3 ADULTS 111
11.4 PEDIATRIC 112
12 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY CANCER TYPE 114
12.1 OVERVIEW 115
12.2 ADENOCARCINOMA 118
12.3 COLORECTAL LYMPHOMA 118
12.4 GASTROINTESTINAL STROMAL TUMORS 119
12.5 CARCINOID TUMORS 120
12.6 OTHERS 120
13 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY END USER 122
13.1 OVERVIEW 123
13.2 HOSPITALS 126
13.3 DIAGNOSTIC CENTERS 126
13.4 CANCER RESEARCH CENTERS 127
13.5 AMBULATORY SURGICAL CENTERS 128
13.6 ACADEMIC INSTITUTES 128
13.7 OTHERS 129
14 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, BY REGION 131
14.1 MIDDLE EAST AND AFRICA 132
14.1.1 SOUTH AFRICA 142
14.1.2 SAUDI ARABIA 147
14.1.3 U.A.E. 152
14.1.4 EGYPT 157
14.1.5 ISRAEL 162
14.1.6 REST OF MIDDLE EAST AND AFRICA 167
15 MIDDLE EAST & AFRICA COLORECTAL CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE 168
15.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA 168
16 SWOT ANALYSIS 169
17 COMPANY PROFILE 170
17.1 F. HOFFMANN- LA ROCHE LTD 170
17.1.1 COMPANY SNAPSHOT 170
17.1.2 REVENUE ANALYSIS 170
17.1.3 COMPANY SHARE ANALYSIS 171
17.1.4 PRODUCT PORTFOLIO 171
17.1.5 RECENT DEVELOPMENT 171
17.2 KONINKLIJKE PHILIPS N.V. 172
17.2.1 COMPANY SNAPSHOT 172
17.2.2 REVENUE ANALYSIS 172
17.2.3 COMPANY SHARE ANALYSIS 173
17.2.4 PRODUCT PORTFOLIO 173
17.2.5 RECENT DEVELOPMENT 173
17.3 THERMO FISHER SCIENTIFIC INC. 175
17.3.1 COMPANY SNAPSHOT 175
17.3.2 REVENUE ANALYSIS 175
17.3.3 COMPANY SHARE ANALYSIS 176
17.3.4 PRODUCT PORTFOLIO 176
17.3.5 RECENT DEVELOPMENT 176
17.4 ILLUMINA, INC. 177
17.4.1 COMPANY SNAPSHOT 177
17.4.2 REVENUE ANALYSIS 177
17.4.3 COMPANY SHARE ANALYSIS 178
17.4.4 PRODUCT PORTFOLIO 178
17.4.5 RECENT DEVELOPMENT 178
17.5 QUEST DIAGNOSTICS INCORPORATED 179
17.5.1 COMPANY SNAPSHOT 179
17.5.2 REVENUE ANALYSIS 179
17.5.3 COMPANY SHARE ANALYSIS 180
17.5.4 PRODUCT PORTFOLIO 180
17.5.5 RECENT DEVELOPMENT 180
17.6 ABBOTT 181
17.6.1 COMPANY SNAPSHOT 181
17.6.2 REVENUE ANALYSIS 181
17.6.3 PRODUCT PORTFOLIO 182
17.6.4 RECENT DEVELOPMENT 182
17.7 AGILENT TECHNOLOGIES, INC. 183
17.7.1 COMPANY SNAPSHOT 183
17.7.2 REVENUE ANALYSIS 183
17.7.3 PRODUCT PORTFOLIO 184
17.7.4 RECENT DEVELOPMENT 184
17.8 BD 185
17.8.1 COMPANY SNAPSHOT 185
17.8.2 REVENUE ANALYSIS 185
17.8.3 PRODUCT PORTFOLIO 186
17.8.4 RECENT DEVELOPMENT 186
17.9 BEIJING O&D BIOTECH CO., LTD. 187
17.9.1 COMPANY SNAPSHOT 187
17.9.2 PRODUCT PORTFOLIO 187
17.9.3 RECENT DEVELOPMENT 187
17.10 BIOFIRE DIAGNOSTICS 188
17.10.1 COMPANY SNAPSHOT 188
17.10.2 REVENUE ANALYSIS 188
17.10.3 PRODUCT PORTFOLIO 189
17.10.4 RECENT DEVELOPMENT 189
17.11 BIO-RAD LABORATORIES, INC. 190
17.11.1 COMPANY SNAPSHOT 190
17.11.2 REVENUE ANALYSIS 190
17.11.3 PRODUCT PORTFOLIO 191
17.11.4 RECENT DEVELOPMENT 191
17.12 CANON MEDICAL SYSTEMS CORPORATION. 192
17.12.1 COMPANY SNAPSHOT 192
17.12.2 REVENUE ANALYSIS 192
17.12.3 PRODUCT PORTFOLIO 193
17.12.4 RECENT DEVELOPMENT 193
17.13 FONAR CORP. 194
17.13.1 COMPANY SNAPSHOT 194
17.13.2 REVENUE ANALYSIS 194
17.13.3 PRODUCT PORTFOLIO 195
17.13.4 RECENT DEVELOPMENT 195
17.14 FUJIFILM CORPORATION 196
17.14.1 COMPANY SNAPSHOT 196
17.14.2 REVENUE ANALYSIS 196
17.14.3 PRODUCT PORTFOLIO 197
17.14.4 RECENT DEVELOPMENT 197
17.15 GE HEALTHCARE. 198
17.15.1 COMPANY SNAPSHOT 198
17.15.2 REVENUE ANALYSIS 198
17.15.3 PRODUCT PORTFOLIO 199
17.15.4 RECENT DEVELOPMENT 199
17.16 HOLOGIC, INC. 200
17.16.1 COMPANY SNAPSHOT 200
17.16.2 REVENUE ANALYSIS 200
17.16.3 PRODUCT PORTFOLIO 201
17.16.4 RECENT DEVELOPMENT 201
17.17 MEDONICA CO. LTD 202
17.17.1 COMPANY SNAPSHOT 202
17.17.2 PRODUCT PORTFOLIO 202
17.17.3 RECENT DEVELOPMENT 202
17.18 MERCK KGAA 203
17.18.1 COMPANY SNAPSHOT 203
17.18.2 REVENUE ANALYSIS 203
17.18.3 PRODUCT PORTFOLIO 204
17.18.4 RECENT DEVELOPMENT 204
17.19 MINFOUND MEDICAL SYSTEMS CO., LTD 205
17.19.1 COMPANY SNAPSHOT 205
17.19.2 PRODUCT PORTFOLIO 205
17.19.3 RECENT DEVELOPMENT 205
17.20 MYRIAD GENETICS, INC. 206
17.20.1 COMPANY SNAPSHOT 206
17.20.2 REVENUE ANALYSIS 206
17.20.3 PRODUCT PORTFOLIO 207
17.20.4 RECENT DEVELOPMENT 207
17.21 NEUSOFT CORPORATION 208
17.21.1 COMPANY SNAPSHOT 208
17.21.2 REVENUE ANALYSIS 208
17.21.3 PRODUCT PORTFOLIO 209
17.21.4 RECENT DEVELOPMENT 209
17.22 PLEXBIO 210
17.22.1 COMPANY SNAPSHOT 210
17.22.2 PRODUCT PORTFOLIO 210
17.22.3 RECENT DEVELOPMENT 210

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.